Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Daily Digest.
Press releases published on June 2, 2025
DEADLINE APPROACHING: Berger Montague Advises BigBear.ai Holdings (NYSE: BBAI) Investors to Inquire About a Securities Fraud Class Action by June 10, 2025
GlobeNewswire
·
June 2, 2025
PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against BigBear.ai Holdings, Inc. (“BigBear” or the “Company”) (NYSE: BBAI) on behalf of purchasers of BigBear …
A. Duie Pyle Recognized as GEODIS 2025 LTL Carrier of the Year
GlobeNewswire
·
June 2, 2025
WEST CHESTER, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- A. Duie Pyle (Pyle), a premier 101-year-old, family-owned and operated provider of asset and non-asset-based supply chain solutions, today announces that it has been honored as a 2025 LTL Carrier of the …
TELA Bio Appoints Jeffrey Blizard as President
GlobeNewswire
·
June 2, 2025
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President …
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
GlobeNewswire
·
June 2, 2025
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. …
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
GlobeNewswire
·
June 2, 2025
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a …
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
GlobeNewswire
·
June 2, 2025
- Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal Lymphopoietin (TSLP) - - Top Line Results Expected in the Second Half of 2026 - WAYNE, Pa., June …